PDCD1 and glioblastoma: In a preclinical GBM model, combinatorial therapy of PD1 and LAG-3 blockade showed increased survival over no treatment, but the survival benefit did not reach statistical significance when compared to that of either anti-PD1 or anti LAG-3 therapy alone (87).